M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact BioSpaceMerck will use Protillion Biosciences' tech to design biologic therapies for therapies across undisclosed indications.Read full story pharminent June 17, 2026 (Last updated: June 17, 2026) BioSpace Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Moderna builds commercial muscle as new launches loomNext: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
